Targeted
Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology
company that develops and distributes prescription medical foods to
physicians and pharmacies, today announced the launch of a new division
that will specialize in the manufacturing and distribution of a
proprietary line of dietary supplements.
The products, currently in the research and development phase, include a
nasal decongestant, sleep aid, an appetite suppressant, a formula for
pain and a formula that supports healthy cognitive performance. The
products utilize the company’s patented targeted cellular technology
platform to increase the effectiveness of milligram amounts of
neurotransmitter precursors and “swish and swallow” system that is
designed to allow digestive enzymes in saliva to initiate and facilitate
digestion.
The first product is scheduled to be launched on November 1, 2013, and
will be an oral dietary supplement featuring a proprietary sinuhealth
blend designed to support healthy sinus and immune function, and help
relieve nasal congestion, sinus pressure and runny nose associated with
allergies and colds.
“We are pleased to announce the development of an over-the-counter
product line and introduce a new technology that enhances the digestion
processes by allowing salivary enzymes to function,” said William Shell,
M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc.
“Our company is committed to innovating healthcare processes and
providing physicians, patients, and health conscious consumers with the
most effective and safe therapeutic options for health and wellness.”
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops prescription medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company manufactures 10 proprietary
prescription-only medical foods, as well as 48 convenience packed kits,
which pair a medical food and branded or generic pharmaceutical. These
prescription medical foods and therapeutic systems are sold to
physicians and pharmacies in the U.S. through the company’s subsidiary, Physician
Therapeutics. These proprietary medications represent a novel
approach to the management of certain disease states, focusing on safety
and efficacy without the deleterious side effects of traditional, high
dose prescription drugs. The company also is developing nutrient-based
systems for oral stimulation of progenitor stem cells that differentiate
into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma’s business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaim any obligation or
undertaking to update or revise any forward-looking statement contained
herein to reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances upon which
any statement is based.
Copyright Business Wire 2013